Portal de Periódicos da CAPES

Comparação entre o uso do midazolam e da dexmedetomidina na sedação para ressecção transuretral de próstata: síntese de evidências

2020; Volume: 6; Issue: 2 Linguagem: Inglês

2526-1606

Marcela Carvalho Araujo, Bruno Ricciardi Silveira,

Anesthesia and Pain Management

Introduction: A Transurethral Prostate Resection (RTU) is the gold standard method for surgical treatment of benign prostatic hyperplasia, considered clinically effective and economically interesting. Among compounds for RTU sedation, the most discussed are Midazolam and Dexmedetomidine. Aim: To conduct a literature review to compare the use of Midazolam and Dexmedetomidine in sedation for RTU. Method: A research was conducted in the PUBMED database, maintained by the National Institute of Health, in the United States of America. A strategy for selecting the works was as follows: (midazolam [title] OR dexmedetomidine [title]) AND transurethral AND prostate. Results: The search was conducted on June 4, 2020. Initially, 12 papers were identified. In the first selection stage, the titles and abstracts were read, to assess the relevance of each in relation to the topic addressed for this review. After this stage, it was found that 4 studies did not discuss the use of Midazolam or Dexmedetomidine in RTU, being promptly eliminated, resting 8 works to review. Conclusion: Most of the reviewed papers suggest that the sedative of choice in RTU is Dexmedetomidine, due to the reduction or length of stay in the hospital, due to the potential or analytical effect of spinal anesthesia, and to the reduction of agitation of preoperative patient. The medical doctors should pay attention only to a possible reduction in oxygen saturation and heart rate, which can occur with the use of Dexmedetomidine.